are a major contributor to cancer- and treatment-related morbidity and mortality. Exocrine pancreas cancer is one of the most common malignancies associated with thrombosis, with most modern studies reporting incidence ranging from 5% to 27%. 1 – 6
Search Results
Andrew S. Epstein and Eileen M. O'Reilly
Mary F. Mulcahy, Andrew O. Wahl, and William Small Jr.
HA 3rd Moore MJ Anderson J . Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial . J Clin Oncol 1997 ; 15 : 2403 – 2413 . 3 Neoptolemos JP
Kamel Izeradjene and Sunil R. Hingorani
gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial . J Clin Oncol 1997 ; 15 : 2403 – 2413 . 4. Allison DC Piantadosi S Hruban RH . DNA content and other factors associated with ten-year survival
Stuart A. Grossman, Susannah Ellsworth, Jian Campian, Aaron T. Wild, Joseph M. Herman, Dan Laheru, Malcolm Brock, Ani Balmanoukian, and Xiaobu Ye
pancreas cancer; (C) unresected pancreas cancer; and (D) non–small cell lung cancer. Table 3 Relationships Between Survival and Grade III/IV Treatment-Related Lymphopenia were controlled for, a relationship between TRL and survival was
Bin Wu and Lizheng Shi
Pancreas Cancer Olaparib Ongoing (POLO) trial reported the efficacy and safety of maintenance olaparib compared with placebo in patients with MPC with a germline BRCA mutation. 8 Results revealed that maintenance olaparib notably prolonged median
/7/13 Liver-Directed Therapies in Patients With Advanced Neuroendocrine Tumors Expiration Date: 6/4/13 Exocrine Pancreas Cancer and Thromboembolic Events: A Systematic Literature Review Expiration Date: 7/7/13 Monitoring Minimal Residual Disease in
/4/13 Exocrine Pancreas Cancer and Thromboembolic Events: A Systematic Literature Review Expiration Date: 7/7/13 Monitoring Minimal Residual Disease in Acute Myeloid Leukemia: Ready for Prime Time? Expiration Date: 8/7/13 Androgen Deprivation Therapy
CME/CE articles published in previous issues of JNCCN: Exocrine Pancreas Cancer and Thromboembolic Events: A Systematic Literature Review Expiration Date: 7/7/13 Monitoring Minimal Residual Disease in Acute Myeloid Leukemia: Ready
Alok A. Khorana
discussion of this is the subject of my article 4 and beyond the scope of this response. I would like, however, to illustrate this struggle by pointing out that in a randomized clinical trial of prophylaxis in patients with pancreas cancer, VTE during
Andrew D. Boyd and Michelle Riba
Thaler HT . Pain and depression in patients with newly diagnosed pancreas cancer . J Clin Oncol 1995 ; 13 : 748 – 755 . 15. Passik SD Roth AJ . Anxiety symptoms and panic attacks preceding pancreatic cancer diagnosis . Psychooncology